Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature

OBJECTIVE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a relatively novel class of oral medications for the treatment of type 2 diabetes mellitus (T2DM). Their use has increased recently due to their beneficial renal and cardiovascular outcomes, but they come with the rare risk of diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, Serena, Eschler, Deirdre Cocks
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924151/
https://www.ncbi.nlm.nih.gov/pubmed/33851013
http://dx.doi.org/10.1016/j.aace.2020.11.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924151/
https://www.ncbi.nlm.nih.gov/pubmed/33851013
http://dx.doi.org/10.1016/j.aace.2020.11.009

Ejemplares similares